

# MedChem 2004 - Lead Profiling: Myth or Reality?

## Programme

---

**08:00**      **Registration**

**08:50**      **Introduction**

**09:00      Synthesis and Pharmacological Characterization of Novel Epothilone Derivatives.**

Dr Rainer METTERNICH  
(CAPROTEC BIOANALYTICS, Basel, Switzerland)

**09:50      Beyond *in vitro* Activity: Multi-Dimensional Evaluation in the Identification of Quality Lead Series.**

Dr Simona CECCARELLI  
(F. HOFFMANN-LA ROCHE, BASEL, Switzerland)

**10:40**      **Coffee break & poster session**

**11:10**

**Discovery of UCB 44212: A New Pyrrolidone Derivative With Potent Antiepileptic Properties And High Tolerability in Rodent Models of Epilepsy.**

Dr Philippe MICHEL  
(UCB SA, BRAINE-L'ALLEUD, Belgium)

**11:30      The Discovery and Selection of TMC114, a Next Generation HIV-Protease Inhibitor.**

Dr Piet WIGERINCK  
(TIBOTEC, Mechelen, Belgium)

12:20

Lunch

**14:00      Recent Advances in Computer-Aided Drug Design.**

Prof. William L. JORGENSEN  
(YALE UNIVERSITY, New Haven, United States)

**14:50**

**A View of an *in vivo* Toxicologist on Early ADME-Tox Profiling.**

Dr A. LAMPO  
(JOHNSON & JOHNSON, BEERSE, Belgium)

**15:40**      **Coffee break & poster session**

**16:10**      **Hit Selection, Prioritisation and Follow-up: Identification of Leads with Minimum Number of Liabilities.**  
Dr Berthold HINZEN  
(BAYER HEALTHCARE PHARMACEUTICALS, WUPPERTAL, Germany)

**16:30      Design of Selective Kinase Inhibitors: Facts or Fantasy?**

Dr Gerhard MÜLLER  
(PROTEROS FRAGMENTS, Munich, Germany)



